The new Clinical and Translational Core will promote and facilitate clinical and translational studies in hypertension, kidney disorders, and related cardiovascular diseases. The main functions will be: promotion of translational studies, and establishment of synergies between basic scientists, physician scientists, and population scientist;facilitation of new studies including protocol design, IRB submission, coordination of services needed, subject recruitment, data management design;performance of clinical visits;assistance with management of data and biostatistical support;sample processing and analysis;coordination with the CTC, facilities within Tulane Hospital or MCLNO, IRB;and facilitation of education and training in clinical research. Clinical and translational studies will usually be performed within two well equipped facilities: Office of Health Research physically located in the School of Public Health and Tropical Medicine;and Clinical Trials Cooperative located within Tulane Hospital. Both facilities have clinical research laboratories with a wide range of capabilities. The former also has ultrasound capabilities, a variety of equipment for vascular studies, EKG machines, and ability to perform iothalamate glomerular filtration testing. The goal is to facilitate and foster the translation of basic insights into clinical and population studies. This core will extend the existing synergies which have been developed in the first two phases of the COBRE. All of the Core personnel are experienced in clinical investigation and are knowledgeable about the ongoing research within each of the areas involved in the existing COBRE. Therefore the core will be well suited to encourage and promote new investigators into translational studies.
Clinical and translational research in hypertension and renal diseases is an appropriate extension of ongoing basic research at Tulane. These studies have significant opportunity to improve prevention, detection, and treatment of these widespread disorders.
|Liu, Liu; Kashyap, Shreya; Murphy, Brennah et al. (2016) GPER activation ameliorates aortic remodeling induced by salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 310:H953-61|
|Hsu, Raymond K; Chai, Boyang; Roy, Jason A et al. (2016) Abrupt Decline in Kidney Function Before Initiating HemodialysisÂ and All-Cause Mortality: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 68:193-202|
|Pingili, Ajeeth K; Thirunavukkarasu, Shyamala; Kara, Mehmet et al. (2016) 6Î²-Hydroxytestosterone, a Cytochrome P450 1B1-Testosterone-Metabolite, Mediates Angiotensin II-Induced Renal Dysfunction in Male Mice. Hypertension 67:916-26|
|Denburg, Michelle R; Hoofnagle, Andrew N; Sayed, Samir et al. (2016) Comparison of Two ELISA Methods and Mass Spectrometry for Measurement of Vitamin D-Binding Protein: Implications for the Assessment of Bioavailable Vitamin D Concentrations Across Genotypes. J Bone Miner Res 31:1128-36|
|Osis, Gunars; Handlogten, Mary E; Lee, Hyun-Wook et al. (2016) Effect of NBCe1 deletion on renal citrate and 2-oxoglutarate handling. Physiol Rep 4:|
|Anwar, Imran J; Miyata, Kayoko; Zsombok, Andrea (2016) Brain stem as a target site for the metabolic side effects of olanzapine. J Neurophysiol 115:1389-98|
|Navar, L Gabriel (2016) 2016 Young Investigator Award of the American Physiological Society Renal Section. Am J Physiol Renal Physiol :ajprenal.00133.2016|
|Rocco, Michael V; Chapman, Arlene; Chertow, Glenn M et al. (2016) Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol 44:130-40|
|Navaneethan, Sankar D; Roy, Jason; Tao, Kelvin et al. (2016) Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol 27:877-86|
|Amdur, Richard L; Feldman, Harold I; Gupta, Jayanta et al. (2016) Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 11:1546-56|
Showing the most recent 10 out of 184 publications